Champions Oncology, Inc.
NASDAQ Capital MarketTotal Valuation
Champions Oncology, Inc. carries a market capitalization of 79.50M, placing it among publicly traded companies globally. Its enterprise value stands at 98.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 79.50M |
| Enterprise Value | 98.78M |
Share Statistics
Champions Oncology, Inc. currently has 13.89M shares outstanding.
| Shares Outstanding | 13.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Champions Oncology, Inc. trades at a trailing price-to-earnings ratio of 88.18. The price-to-sales ratio is 1.74, and the price-to-book ratio stands at -1.26.
| PE Ratio | 88.18 |
| PS Ratio | 1.74 |
| PB Ratio | -1.26 |
| P/TBV Ratio | 24.96 |
| P/FCF Ratio | 20.54 |
| P/OCF Ratio | 22.97 |
Enterprise Valuation
On an enterprise value basis, Champions Oncology, Inc. trades at an EV/EBITDA multiple of 55.67 and an EV/FCF ratio of 19.87. The EV/Sales ratio of 1.70 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 83.98 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.70 |
| EV / EBITDA | 55.67 |
| EV / EBIT | 83.98 |
| EV / FCF | 19.87 |
Financial Position
Champions Oncology, Inc. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.98 |
| Quick Ratio | 0.93 |
| Debt / Equity | 111.79 |
| Debt / EBITDA | -6.33 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -7.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Champions Oncology, Inc. has paid -55,000.00 in income taxes, reflecting an effective tax rate of 7.06.
| Income Tax | -55,000.00 |
| Effective Tax Rate | 7.06 |
Stock Price Statistics
Champions Oncology, Inc.'s stock has declined approximately -10.96423% over the past 52 weeks. The 50-day moving average sits at 5.94, while the 200-day moving average is 6.45.
| Beta (5Y) | N/A |
| 52-Week Price Change | -10.96423% |
| 50-Day Moving Average | 5.94 |
| 200-Day Moving Average | 6.45 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Champions Oncology, Inc. generated 57.94M in revenue and converted that into -2.28M in net income, yielding earnings per share of -0.17. EBITDA reached -773,000.00, while operating income came in at -2.22M.
| Revenue | 57.94M |
| Gross Profit | 26.58M |
| Operating Income | -2.22M |
| Pretax Income | -2.40M |
| Net Income | -2.28M |
| EBITDA | -773,000.00 |
| EBIT | -2.22M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
Champions Oncology, Inc. holds 7.13M in cash and equivalents against 4.89M in total debt, resulting in a net debt position of -7.13M. Total book value stands at -80.39M, with working capital of -492,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 7.13M |
| Total Debt | 4.89M |
| Net Debt | -7.13M |
| Equity (Book Value) | -80.39M |
| Book Value Per Share | -5.82 |
| Working Capital | -492,000.00 |
Cash Flow
Champions Oncology, Inc. produced 4.39M in operating cash flow over the past twelve months. After subtracting -578,000.00 in capital expenditures, free cash flow totaled 3.82M - equivalent to 0.28 per share.
| Operating Cash Flow | 4.39M |
| Capital Expenditures | -578,000.00 |
| Free Cash Flow | 3.82M |
| FCF Per Share | 0.28 |
Margins
Champions Oncology, Inc. operates with a gross margin of 45.88, reflecting its pricing power and cost economics. The operating margin of -3.84 and net profit margin of -3.94 provide insight into operational efficiency.
| Gross Margin | 45.88 |
| Operating Margin | -3.84 |
| Pretax Margin | -4.14 |
| Profit Margin | -3.94 |
| EBITDA Margin | -1.33 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.09 |
| FCF Yield | 4.87 |
Stock Splits
Champions Oncology, Inc.'s most recent stock split took place on August 12, 2015 with a 12:1 split ratio.
| Last Split Date | 8/12/2015 |
| Split Ratio | 12:1 |
Scores
Champions Oncology, Inc. posts an Altman Z-Score of 0.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.29 |